CN115052877A - 一种氮杂吲哚衍生物的晶型及其应用 - Google Patents

一种氮杂吲哚衍生物的晶型及其应用 Download PDF

Info

Publication number
CN115052877A
CN115052877A CN202180010022.4A CN202180010022A CN115052877A CN 115052877 A CN115052877 A CN 115052877A CN 202180010022 A CN202180010022 A CN 202180010022A CN 115052877 A CN115052877 A CN 115052877A
Authority
CN
China
Prior art keywords
degrees
compound
formula
crystalline form
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180010022.4A
Other languages
English (en)
Other versions
CN115052877B (zh
Inventor
陈正霞
戴美碧
张杨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Lingfang Biomedical Technology Co ltd
Original Assignee
Shenzhen Lingfang Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Lingfang Biomedical Technology Co ltd filed Critical Shenzhen Lingfang Biomedical Technology Co ltd
Publication of CN115052877A publication Critical patent/CN115052877A/zh
Application granted granted Critical
Publication of CN115052877B publication Critical patent/CN115052877B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

公开了一类氮杂吲哚衍生物的晶型及制备方法。

Description

PCT国内申请，说明书已公开。

Claims (30)

  1. PCT国内申请，权利要求书已公开。
CN202180010022.4A 2020-01-15 2021-01-15 一种氮杂吲哚衍生物的晶型及其应用 Active CN115052877B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010042713 2020-01-15
CN202010042713X 2020-01-15
PCT/CN2021/072247 WO2021143875A1 (zh) 2020-01-15 2021-01-15 一种氮杂吲哚衍生物的晶型及其应用

Publications (2)

Publication Number Publication Date
CN115052877A true CN115052877A (zh) 2022-09-13
CN115052877B CN115052877B (zh) 2023-08-22

Family

ID=76863636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180010022.4A Active CN115052877B (zh) 2020-01-15 2021-01-15 一种氮杂吲哚衍生物的晶型及其应用

Country Status (6)

Country Link
US (1) US11919898B2 (zh)
EP (1) EP4092023A4 (zh)
JP (1) JP7432739B2 (zh)
KR (1) KR20220128419A (zh)
CN (1) CN115052877B (zh)
WO (1) WO2021143875A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008124850A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101641351A (zh) * 2006-12-21 2010-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
WO2010059771A1 (en) * 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
CN104710417A (zh) * 2013-12-11 2015-06-17 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
WO2020015744A1 (zh) * 2018-07-19 2020-01-23 南京明德新药研发有限公司 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246529B2 (en) * 2018-07-13 2022-02-15 Northeastern University Method to localize small and high contrast inclusions in ill-posed model-based imaging modalities

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101641351A (zh) * 2006-12-21 2010-02-03 普莱希科公司 用于激酶调节的化合物和方法及其适应症
WO2008124850A1 (en) * 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
WO2010059771A1 (en) * 2008-11-20 2010-05-27 Osi Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]-pyridines and-pyrazines
CN104710417A (zh) * 2013-12-11 2015-06-17 上海科州药物研发有限公司 氮杂吲哚类衍生物及其合成方法
WO2020015744A1 (zh) * 2018-07-19 2020-01-23 南京明德新药研发有限公司 氮杂吲哚衍生物及其作为FGFR和C-Met抑制剂的应用

Also Published As

Publication number Publication date
JP7432739B2 (ja) 2024-02-16
KR20220128419A (ko) 2022-09-20
WO2021143875A1 (zh) 2021-07-22
EP4092023A1 (en) 2022-11-23
US20230322760A1 (en) 2023-10-12
US11919898B2 (en) 2024-03-05
CN115052877B (zh) 2023-08-22
EP4092023A4 (en) 2023-08-02
JP2023510932A (ja) 2023-03-15

Similar Documents

Publication Publication Date Title
CN104011052B (zh) 化合物
AU2011312485B2 (en) Crystalline (R) - (E) -2- (4- (2- (5- (1- (3, 5 -dichloropyridin-4 -yl) ethoxy) - 1H - indazol - 3 - yl) vinyl) -1 H- pyrazol- 1 -yl) ethanol and its use as FGFR inhibitor
RU2639863C2 (ru) Противораковые бензопиразины, действующие посредством ингибирования fgfr-киназ
CN102858765B (zh) 吡唑基喹喔啉激酶抑制剂
CN107746405A (zh) Syk抑制剂
CN104011025A (zh) 作为fgfr激酶调节剂的喹啉
CN114174271B (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
WO2019223766A1 (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
CN115052877B (zh) 一种氮杂吲哚衍生物的晶型及其应用
WO2022048545A1 (zh) 一种吡啶并嘧啶化合物的晶型
CN112480109B (zh) 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
CN114072402B (zh) 作为fgfr和vegfr双重抑制剂的吡啶衍生物
CN109438362B (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
AU2020248834A1 (en) BRD4 inhibitor compound in solid form and preparation method therefor and application thereof
EP4130004A1 (en) Salt and crystalline forms of fgfr4 inhibitor and uses thereof
WO2022161408A1 (zh) 甲基吡唑取代的吡啶并咪唑类化合物的晶型及其制备方法
CN114075135B (zh) 含邻氨基吡啶炔基的化合物的盐及其制备方法和应用
WO2020224585A1 (zh) 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法
WO2019238088A1 (zh) 吡啶并吡啶酮衍生物的盐型及晶型
WO2022268180A1 (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Room 504, Building C1, No. 201 Linghu Avenue, Xinwu District, Wuxi City, Jiangsu Province, 214111

Applicant after: Wuxi Lingfang Biopharmaceutical Technology Co.,Ltd.

Address before: 518045 1312, building 1, Changfu Jinmao building, south of Shihua Road, Fubao community, Fubao street, Futian District, Shenzhen, Guangdong Province

Applicant before: Shenzhen Lingfang Biomedical Technology Co.,Ltd.

GR01 Patent grant
GR01 Patent grant